Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variant JN.1 in critically ill COVID-19 patients: a prospective, multicenter cohort study
de Prost, N.; Audureau, E.; Guillon, A.; Handala, L.; Preau, S.; Guigon, A.; Uhel, F.; Le Hingrat, Q.; Delamaire, F.; Grolhier, C.; Tamion, F.; Moisan, A.; Darreau, C.; Thomin, J.; Contou, D.; Henry, A.; Daix, T.; Hantz, S.; Saccheri, C.; Giordanengo, V.; Pham, T.; Chaghouri, A.; Bay, P.; Pawlotsky, J.; Fourati, S.
Show abstract
A notable increase in severe cases of COVID-19, with significant hospitalizations due to the emergence and spread of JN.1 was observed worldwide in late 2023 and early 2024. During the study period (November 2022-January 2024), 56 JN.1- and 126 XBB-infected patients were prospectively enrolled in 40 French intensive care units. JN.1-infected patients were more likely to be obese (35.7% vs 20.8%; p=0.033) and less frequently immunosuppressed than others (20.4% vs 41.4%; p=0.010). JN.1-infected patients required invasive mechanical ventilation support in 29.1%, 87.5% of them received dexamethasone, 14.5% tocilizumab and none received monoclonal antibodies. Day-28 mortality of JN.1-infected patients was 14.6%.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.